App-Quantinova.ai

Evaluation of neurological improvements in secondary progressive multiple sclerosis patients treated with myeloid targeted immune modulator MIS416 (P5.362)

Gill Webster - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

MIS 416

The “Worried Well”: Characteristics of Cognitively Normal Patients Presenting to a Rural and Remote Memory Clinic (P6.072)

Ryan Verity - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Validation of i1 Biometrics Vector MouthGuard: Measuring Head Impact Frequency in Sport (S48.008)

Geoffrey McKendry - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Disability and mortality after permanent feeding tube placement in patients with acute stroke (P3.107)

Raed Joundi - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

GRIN1 polymorphisms do not affect susceptibility or phenotype in NMDA receptor encephalitis (P6.190)

Gregory Day - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

A case of LGMD2A caused by a novel splice site mutation identified by RNA-seq (P1.114)

Stefan Nicolau - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Vitamin Deficiencies in Patients with Myopathies and Other Neuromuscular Conditions (P2.115)

Dubravka Dodig - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Ergocalciferol

Five-year recurrence rate following stroke in the Mashhad Stroke Incidence Study: A population-based study of stroke in the Middle East (P6.276)

Amin Amiri - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Increased sensitivity of 2015 Neuromyelitis Optica Spectrum Disorder (NMOSD) diagnostic criteria in older, non-Asian subjects (P2.332)

Karly Stratos - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Lateralization of fine motor actions in Tourette syndrome persisting through adulthood (P6.026)

Davide Martino - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Quantitative EEG Detects REM Sleep to Enhance Epileptogenic Zone Localization (P4.249)

Marcus Ng - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Neuropathological Basis of Apolipoprotein E Genotype on Psychosis in Alzheimer’s Disease (P2.089)

Julia Kim - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Oculomotor function and white matter integrity in patients with post-concussion syndrome (S9.003)

Foad Taghdiri - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Unilateral papilledema in idiopathic intracranial hypertension: a report of two cases and literature review (P5.185)

Emily Swinkin - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

SYNE1 mutations cause adult onset autosomal recessive ataxia with retained reflexes in Brazilian patients (P3.004)

Maria Thereza Drumond Gama - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

The synergistic interaction between amyloid and tau PET in the brain’s default mode network determines the clinical status in early Alzheimer’s disease. (P4.100)

Tharick A. Pascoal - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Florbetapir

Inflammasome Activation in Glioblastoma Multiforme (P1.172)

Erin Balcom - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Myelin water imaging provides evidence of long-term remyelination and neuroprotection in Alemtuzumab treated multiple sclerosis patients (P5.335)

Irene Vavasour - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Alemtuzumab

Rare Cases of Thrombotic and Embolic Stroke with Hypereosinophilia (P1.295)

Deana Finelli - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Thrombomodulin alfa

Evaluation of abuse potential of brivaracetam in healthy recreational CNS depressant users (P6.243)

Kerri Schoedel - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Brivaracetam

Filters

28841 Abstracts